

Global Leader in the Biopharma Industry



We are GC Biopharma

GC Biopharma Major Business Portfolio

GC Biopharma has been accumulating expertise in plasma derivatives, vaccines, recombinant proteins, and chemical prescription drugs.

Innovative rare disease medicines

Globally leading plasma-derived medicines

Globally leading diverse vaccines

Trusted expertise in aseptic filling solution

Total solution for mRNA medicines

Hunter syndrome treatment

Albumin, Human immunoglobulin

Varicella and Flu vaccines

CMO (fill & finish)

CDMO (mRNA/LNP)

GC Biopharma At a Glance



It is our MISSION to contribute to the healthy lives of humankind and it is our VISION to be a global leader in the health industry.

1967

Established

1989

IPO (S. Korea)

6,256+

Employees

\$16.96 Bil

'24 Revenue*

150+

Commercial Products

68

Export Countries

*Consolidated Accounting Standards



No.1

- Plasma derivatives
- Vaccines
- Rare disease business in S. Korea



2023

- IVIG 10% FDA Approval
- MPS IIIA Orphan Drug Designation




2030

- Global sales + 1.9 Bil USD
- Over +68 Countries

Dedicated Organization

Mission to the healthy lives & Vision to be a global leader




GC Biopharma has solidified its position as **Korea's 1st and best in healthcare.**
We are continuously shaping a healthier future worldwide.

Research & Development Investments

GC Biopharma's researchers Continue to rise To the challenge of saving lives

R&D to Revenue Ratio



R&D workforce
[As of June 2024]



Total **428** persons

- Master's / Doctorate : 299 persons
- Bachelor's : 82 persons
- Others : 47 persons

Global Network

Mission to the healthy lives & Vision to be a global leader



8 Global operations + 3 branch offices across the world

Medicines Access

Unlimited dedication to the development of safer and more effective treatments

Core Products



Vaccines

- Flu Vaccine
- Varicella Vaccine
- Td Vaccine & 5 Others



Blood Plasma Derived

- Albumin
- Human Immunoglobulin G
- Human Hepatitis B
- Immunoglobulin (HBIG) + 10 Others



Rare Disease

- ERT for Hunter syndrome
- Hemophilia A/B type
- Alagille syndrome

Tumor

Treatment for Severe Neutrophil Reduction

Metabolic & Cardiovascular

High blood pressure, Dyslipidemia, Diabetes

OTC Drugs

Vitamins, Painkillers, Patches

Boldness and Passion in our History

This is the path GC Biopharma has taken

1967

Establishment

For half a century, GC has taken the difficult path of developing 'Medicinal drugs that are difficult to make, but essential' with the devotion to help build a society where everyone can enjoy a happy life without suffering from diseases.

1971

1st Plasma fractionation plant

Korea's 1st blood plasma fractionation plant

1983

World's 3rd vaccine against hepatitis B

Becomes third pharmaceutical company in the world to obtain product license for hepatitis-B vaccine [Hepavax-B]


1988

World's 1st vaccine against hemorrhagic fever with renal syndrome

Becomes first pharmaceutical company in the world to obtain product license for vaccine against hemorrhagic fever with renal syndrome [Hantavax]


Boldness and Passion in our History

This is the path GC Biopharma has taken



Boldness and Passion in our History

This is the path GC Biopharma has taken



2021

World's 1st
Antibiotic – free varicella vaccine



WHO Pre-Qualification
for BARYCELA inj.

WHO Pre-Qualification for BARYCELA inj.

WHO Pre-Qualification for Hwasun plant

WHO Pre-Qualification
for Filling and Finish plant of Ochang Plant

2023

2021


World's 1st ERT
for Neuronopathic MPSII

The world's 1st ERT for Neuronopathic MPS II
[Hunterase ICV Inj.] has been developed and approved in
Japan



2023




IVIG 10% FDA Approval &
Successful launching



We always welcome the challenge of developing new medicine.

R&D Pipeline (as of October 2025)

Business key update

	Preclinical >>>	Phase I >>>	Phase II >>>	Phase III >>>	Registration / Approved
 <p>Plasma Derivatives</p>	<p>GC5125 vWF deficiency</p> <p>GC5136 PID (SC IVIG)</p>			<p>GC5107 US PID- IVIG (Pediatric)</p>	<p>GC5107 US PID- IVIG</p>
 <p>Vaccines</p>	<p>GC4002 mRNA Flu vaccine</p> <p>GC3114B TIV-HD</p>	<p>GC4006A mRNA COVID vaccine</p>	<p>MG1120/CRV-101 US Shingles vaccine</p> <p>MG1111 Varicella vaccine (2 dose)</p> <p>GC3111 Tdap vaccine</p>		<p>MG1111 Varicella vaccine</p> <p>GC1109 Anthrax vaccine</p> <p>GC1109 H5N1 pandemic vaccine</p>
 <p>Innovative medicines</p>	<p>GC4003 (mRNA) SSADH deficiency</p> <p>GC1126 TTP</p> <p>GC2126 Gangliosidosis</p>	<p>MG1113 Hemophilia A/B</p> <p>GC1123 KR Hunter syndrome (severe type)</p> <p>GC1130 US MPSIIIA (Ph1)</p>	<p>GC1134 US Fabry disease (Ph1/2)</p>	<p>GC1138 Glanzmann's disease</p>	<p>GC2127 Alagille syndrome</p> <p>GC1101 China Hemophilia A</p> <p>GC1111 Hunter syndrome</p>



Site 1_Ochang

Brand New Manufacturing Sites



Established	2010 / 2019
Location	Ochang, South Korea
Area (F&F)	131,959 m ²
Products	Plasma & Recombinant Proteins, mRNA, AAV, C>
Key Services	Aseptic Fill & Finish, Logistics
Containers	Vials

- ☑ WHO PQ/ Ministry of Food and Drug Safety authorization completed/ FDA
- ☑ Formulation - filling - Lyo - packaging - release
- ☑ High speed Isolator line (Vial) & BSL-2
- ☑ Automatic visual inspection
- ☑ Automatic labeling and packaging system
- ☑ Automated warehouse-barcode system



Site 2_Hwasun (WHO PQ approved plant for global vaccine production)

Brand New Manufacturing Sites




Established	2010
Location	Hwasun, South Korea
Area (F&F)	98,963 m ²
Products	Vaccines
Key Services	Aseptic Fill & Finish
Containers	Vial & Pre-filled syringe

- ✔ WHO PQ/ Ministry of Food and Drug Safety authorization completed/ FDA
- ✔ Formulation - filling - Lyo - packaging - release
- ✔ Liquid Vials Filling (BSL 2 Available)
- ✔ Automatic visual inspection
- ✔ Automatic labeling and packaging system
- ✔ Packaging Aggregation system / serialization
- ✔ mRNA Facilities (Drug Substance) for 2025




Our Customized Aseptic Fill & Finish Service

Brand New Manufacturing Sites



CMO Professional Personnel
(DP+QM+RA)



Filling Solutions

From small to large scale production
(5L - 1,000L)

Packaging Solutions

Diverse packaging format













Quality Management System

Regulatory track records
(68 countries)

Our Customized Aseptic Fill & Finish Service

No.1 Aseptic Fill & Finish CMO Capacity in Korea

All our Quality System Satisfies cGMP

Change Control System 	Deviation System 	Out of Specification System 
Supplier Management System 	Product Complaint System 	Training System 
Warehousing System 	Recall System 	IT System 
Equipment Life Cycle Management System 	Laboratory System 	Document Management System 



www.gcbiopharma.com

